Chromogranin A (CgA)
Chromogranin A is a neuroendocrine tumor marker, yet one of the commonest reasons it reads high is a pill millions take for reflux. Here is why, and what to do before the draw.
Part of the Tumor Markers — see all 11 values together, including Alpha-Fetoprotein, Beta-hCG, Cancer Antigen 125.
A high chromogranin A reading sends people straight to the worst search results, yet a common stomach-acid drug can drive this tumor marker sky-high in someone who has no tumor at all. That is the strange thing about chromogranin A, abbreviated CgA: it is a real marker for neuroendocrine tumors, the kind the National Cancer Institute lists among the tumor markers used to help with diagnosis and to follow treatment, but it is also one of the easiest blood tests to set off by accident.
Think of it as a smoke alarm mounted in the kitchen. The alarm works. But the antacid sitting in the cabinet keeps tripping it, so the very pill that has nothing to do with a fire is the thing that keeps the warning shrieking. With chromogranin A, the pill is a proton pump inhibitor, the reflux drug millions of people take, and it can push the reading into territory that looks alarming on paper.
CgA is a protein stored and released by neuroendocrine cells throughout the body, which is why a tumor made of those cells can flood the blood with it. The same biology is what makes the test useful and what makes it twitchy. It is measured in ng/mL on this lab's report, which is the same unit as ug/L, so a value reads identically in either notation. Because the test is not specific to cancer, the number on its own settles very little; it earns meaning only next to your medications, your kidney function and any imaging.
How a chromogranin A result is usually read
ng/mLA normal CgA makes an active, secreting neuroendocrine tumor less likely, but the marker is not sensitive enough to rule one out by itself.
A common picture in people on a proton pump inhibitor or with reduced kidney function. Worth repeating after the confounder is addressed before anything else.
Can come from a tumor, but a PPI alone has been documented pushing CgA roughly tenfold. Imaging and a medication review sort out which.
The zones above carry a deliberate hedge, because chromogranin A is not standardized. There is no single universal assay; labs use different kits with different reference ranges, so the cutoff that counts as high genuinely depends on where your blood was tested. That is also why the experts treat any single number as a starting point rather than a verdict.
Why a heartburn pill fakes a high reading
The mechanism is worth spelling out, because most lab pages mention "stop your PPI" as a one-line caveat and never say why a reflux drug touches a tumor marker. A proton pump inhibitor suppresses stomach acid. The stomach notices the low acid and ramps up gastrin to compensate. Sustained high gastrin then drives the enterochromaffin-like cells in the stomach lining to multiply, and those cells release chromogranin A. No tumor is involved anywhere in that chain. The drug simply manufactures the signal the test is built to catch.
How big is the artifact? In a British Journal of Cancer study, people with no evidence of disease saw their median chromogranin A fall from 390 to 56 ug/L once the PPI was withheld for two weeks; even patients with stable disease dropped from 618 to 318. A separate case report in Case Reports in Endocrinology is starker still: a person on the PPI rabeprazole reached 176 U/L against a reference of under 17.2 U/L, a roughly tenfold elevation squarely in the range people associate with disease, which then normalized within about three weeks of stopping the drug.
That is why the International Journal of Endocrinology review calls PPIs one of the commonest causes of a spuriously elevated CgA and advises stopping them for at least about two weeks before the draw so the effect fully clears. H2 blockers and some antidepressants nudge the same gastrin pathway, so they are not an automatic clean substitute.
Getting a clean chromogranin A reading
-
1
Tell the ordering doctor every acid drug you take
Talk to the clinician who ordered the test before changing anything. Proton pump inhibitors are the headline confounder, and they need to know you are on one to read the result.
-
2
Ask about pausing the PPI, and for how long
The International Journal of Endocrinology review describes discontinuing PPIs for at least about two weeks before the draw. Whether that is safe for you, and what to use for reflux meanwhile, is the doctor's call, not a do-it-yourself step.
-
3
Don't assume an H2 blocker is a free swap
H2 antagonists work on the same gastrin pathway, so switching can blunt the artifact without erasing it. Let the clinician decide on timing or a substitute.
-
4
Stick to one lab when you retest
Because the assay is not standardized, comparing across labs is comparing different yardsticks. One lab over time is what makes a trend mean anything.
What else lifts chromogranin A
Even with the PPI sorted out, chromogranin A is a chatty marker that responds to several common conditions, which is exactly why it is interpreted alongside imaging and clinical findings rather than alone. The most frequent everyday non-tumor drivers, per the International Journal of Endocrinology review and a 2025 narrative review on its gastrointestinal causes, are medications, atrophic gastritis and impaired kidney function.
Non-tumor reasons chromogranin A runs high
-
Proton pump inhibitors
The headline cause. Acid suppression raises gastrin, which drives the stomach cells that release CgA.
-
Reduced kidney function
CgA is partly cleared by the kidneys, so impaired clearance lets it accumulate in the blood.
-
Chronic atrophic gastritis
Long-standing inflammation of the stomach lining is a recognised gastrointestinal driver.
-
Inflammatory and irritable bowel conditions
Both inflammatory bowel disease and irritable bowel syndrome appear on the review's list of elevators.
-
Liver disease
Chronic hepatitis and cirrhosis can raise the level.
-
Cardiovascular conditions
The review lists arterial hypertension and cardiac insufficiency among the causes.
When chromogranin A is being used the way it was designed, as a neuroendocrine tumor marker, its accuracy still varies a lot by tumor type. Reported sensitivity runs roughly 60 to 100 percent and specificity roughly 70 to 100 percent depending on the tumor, which is another reason no clinician treats it as a standalone answer.
Chromogranin A in context
Chromogranin A is rarely read in isolation. It sits in the broader tumor markers picture, where the question is never one number but the pattern: how it moves, what imaging shows, and whether a confounder explains the value. For people being worked up for a secreting tumor, calcium and hormone testing such as cortisol may sit alongside it, while protein markers like CEA, CA 19-9 and AFP answer different questions entirely. Our guide to reading tumor markers walks through why these tests are followed over time rather than judged on a single draw.
That trend framing matters most here. Because chromogranin A swings with medications and assay choice, a single value is fragile, but the direction it moves once confounders are controlled is informative. When the marker is used to follow a neuroendocrine tumor, how often it gets rechecked is set by the treatment plan rather than by you, and a repeat after pausing a PPI follows its own timing. If yours came back high, the most productive first move is rarely panic; it is a conversation with the ordering doctor about what you were taking when the blood was drawn.
Sources
- NCI - Tumor Markers Commonly Used to Aid Diagnosis or Treatment
- Chromogranin A: From Laboratory to Clinical Aspects of Patients with Neuroendocrine Tumors (International Journal of Endocrinology, 2018)
- Discontinuation of proton pump inhibitors during assessment of chromogranin A levels in patients with neuroendocrine tumours (British Journal of Cancer, 2011)
- Malignant Range Elevation of Serum Chromogranin A due to Inadvertent Use of Proton Pump Inhibitor (Case Reports in Endocrinology, 2012)
- Rethinking chromogranin A: gastrointestinal factors beyond neuroendocrine neoplasms - a narrative review (2025)
Written and reviewed by BloodSight Editorial Team · Last updated
See your Chromogranin A on one timeline.
BloodSight calibrates the reference range to your sex, age, and lab — and shows every value across every visit.
In your personal range
Normal ranges
| Group | Range | Unit |
|---|---|---|
| Adult Male | 0–95 | ng/mL |
| Adult Female | 0–95 | ng/mL |
Reference ranges may vary by laboratory and individual factors.
Chromogranin A — Common Questions
Why is my chromogranin A high if I don't have cancer?
Do I need to stop my omeprazole or PPI before a chromogranin A test, and for how long?
How high can a PPI push chromogranin A, and could it look like a tumor?
Can kidney disease or heart failure raise chromogranin A?
Why is my chromogranin A different at two labs?
Can I switch to an H2 blocker instead of stopping acid treatment before the test?
Disclaimer
This content is for informational and educational purposes only. It is not intended as medical advice, diagnosis, or treatment recommendation. Reference ranges may vary by laboratory. Always discuss your results with a qualified healthcare professional.
Related Tests
Carcinoembryonic antigen is a watch-post, not a search party. Its real job starts after a cancer is found: tracking whether the number creeps back up between scans.
CA 19-9 is the main blood marker doctors track in pancreatic and bile-duct cancers. Its strangest quirk: a sizable minority of people are simply built not to produce it at all.
AFP is read as a cancer marker, but a liver healing from hepatitis or cirrhosis raises it too. Here is how to read the number without panic.
Serum calcium is the flattest line on most lab reports, a number defended rather than left to drift. Its stillness is the whole reason a real shift carries weight.
Cortisol runs on a daily timetable, peaking around the moment you wake and thinning out by midnight. Read without the clock beside it, the number on your report can look alarming and mean almost nothing.